Drug Profile
EPI 589
Alternative Names: (R)-troloxamide quinone; EPI-589; Kinoquinone - PTC TherapeuticsLatest Information Update: 05 Apr 2022
Price :
$50
*
At a glance
- Originator Edison Pharmaceuticals
- Developer PTC Therapeutics; Sumitomo Pharma
- Class Alkadienes; Amides; Antidementias; Antiparkinsonians; Benzoquinones; Cyclohexenes; Small molecules
- Mechanism of Action Antioxidants; NAD(P)H dehydrogenase (quinone) modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Amyotrophic lateral sclerosis; Parkinson's disease